Julian David Gillmore
#152,503
Most Influential Person Now
Julian David Gillmore's AcademicInfluence.com Rankings
Julian David Gillmorecomputer-science Degrees
Computer Science
#8126
World Rank
#8547
Historical Rank
Informatics
#49
World Rank
#51
Historical Rank
Julian David Gillmorephilosophy Degrees
Philosophy
#8495
World Rank
#11888
Historical Rank
Logic
#5526
World Rank
#6932
Historical Rank
Download Badge
Computer Science Philosophy
Julian David Gillmore's Degrees
- Doctorate Medicine Harvard University
- PhD Biomedical Informatics Stanford University
Why Is Julian David Gillmore Influential?
(Suggest an Edit or Addition)Julian David Gillmore's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis (2016) (1108)
- Natural history and outcome in systemic AA amyloidosis. (2007) (847)
- Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. (2002) (607)
- Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein (2001) (523)
- Systemic amyloidosis (2016) (458)
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy (2003) (420)
- Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis (2015) (416)
- A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. (2013) (351)
- Native T1 mapping in transthyretin amyloidosis. (2014) (349)
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. (2021) (343)
- A new staging system for cardiac transthyretin amyloidosis (2018) (333)
- T1 mapping and survival in systemic light-chain amyloidosis (2014) (321)
- Antibodies to human serum amyloid P component eliminate visceral amyloid deposits (2010) (311)
- A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. (2015) (299)
- Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. (2015) (296)
- Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome (2013) (289)
- Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. (2010) (279)
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (279)
- Magnetic Resonance in Transthyretin Cardiac Amyloidosis. (2017) (268)
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. (2011) (258)
- CMR-based differentiation of AL and ATTR cardiac amyloidosis. (2014) (241)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (2019) (235)
- Systemic Amyloidosis in England: an epidemiological study (2013) (233)
- Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. (2007) (229)
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. (2021) (217)
- The genetic basis of autosomal dominant familial Mediterranean fever. (2000) (203)
- Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. (2019) (200)
- Bleeding symptoms and coagulation abnormalities in 337 patients with AL‐amyloidosis (2000) (192)
- Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations (2014) (190)
- Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. (2014) (175)
- AMYLOIDOSIS: A REVIEW OF RECENT DIAGNOSTIC AND THERAPEUTIC DEVELOPMENTS (1997) (169)
- Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. (2012) (162)
- Native T1 and Extracellular Volume in Transthyretin Amyloidosis. (2019) (148)
- Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. (2015) (147)
- Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. (2012) (141)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 1 OF 2-EVIDENCE BASE AND STANDARDIZED METHODS OF IMAGING. (2019) (141)
- Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. (2009) (139)
- Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis (2017) (136)
- A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. (2015) (132)
- Myocardial Edema and Prognosis in Amyloidosis. (2018) (132)
- Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease (2008) (131)
- Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. (2016) (129)
- Amyloidosis and the respiratory tract (1999) (129)
- Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis (2010) (125)
- Outcome in renal Al amyloidosis after chemotherapy. (2011) (123)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization (2019) (121)
- Guidelines on the diagnosis and investigation of AL amyloidosis (2015) (118)
- Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. (2006) (118)
- Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. (2011) (116)
- Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) (2014) (113)
- Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid (2017) (109)
- Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy (2020) (109)
- Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (2021) (106)
- Guidelines on the management of AL amyloidosis (2015) (106)
- A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. (2019) (106)
- Pyrin/marenostrin mutations in familial Mediterranean fever. (1998) (104)
- A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis (2015) (102)
- Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. (2019) (101)
- SAA1 alleles as risk factors in reactive systemic AA amyloidosis. (1998) (101)
- Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. (2020) (100)
- Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis (2015) (100)
- Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. (2015) (98)
- Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. (2001) (98)
- Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles. (2019) (95)
- Natural history and outcome of light chain deposition disease. (2015) (94)
- Perspectives in treatment of AL amyloidosis (2008) (93)
- A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue (2015) (93)
- Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis (2018) (91)
- Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis (2014) (88)
- AA amyloidosis complicating the hereditary periodic fever syndromes. (2003) (87)
- Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. (2020) (86)
- Pathophysiology and treatment of systemic amyloidosis (2013) (85)
- Outcome of autologous stem cell transplantation for AL amyloidosis in the UK (2006) (83)
- CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. (2018) (79)
- Renal Transplantation in Systemic Amyloidosis—Importance of Amyloid Fibril Type and Precursor Protein Abundance (2013) (79)
- Structure, Folding Dynamics, and Amyloidogenesis of D76N β2-Microglobulin (2013) (77)
- Systemic amyloidosis and the gastrointestinal tract (2009) (74)
- Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. (2000) (74)
- Hereditary renal amyloidosis associated with variant lysozyme in a large English family. (1999) (73)
- Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. (2002) (71)
- Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. (2018) (70)
- Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis (2006) (70)
- Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? (2004) (70)
- AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. (2008) (69)
- Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic StenosisCLINICAL PERSPECTIVE (2016) (68)
- Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression. (2020) (68)
- Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers (2014) (68)
- High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. (2019) (68)
- Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. (2001) (64)
- Hereditary lysozyme amyloidosis – phenotypic heterogeneity and the role of solid organ transplantation (2012) (63)
- Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature (2013) (55)
- A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK (2015) (54)
- Afro-Caribbean Heart Failure in the United Kingdom: Cause, Outcomes, and ATTR V122I Cardiac Amyloidosis. (2016) (54)
- Allogeneic bone marrow transplantation for systemic AL amyloidosis (1998) (54)
- European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis. (2016) (52)
- Plasminogen activation triggers transthyretin amyloidogenesis in vitro (2018) (52)
- Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. (2015) (51)
- High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis. (2019) (50)
- Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre (2017) (48)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. (2019) (47)
- Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study (2020) (45)
- The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis (2019) (45)
- Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (2020) (44)
- Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue—a case series and genetic exploration (2017) (44)
- D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile (2016) (43)
- The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. (2012) (43)
- Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens (2014) (43)
- Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis (2020) (41)
- Outcomes of Heart Transplantation for Cardiac Amyloidosis: Subanalysis of the Spanish Registry for Heart Transplantation (2009) (40)
- The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. (2002) (40)
- Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner (2020) (39)
- Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred (2014) (39)
- High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. (2008) (38)
- High-dose melphalan and stem cell rescue for AL amyloidosis (1999) (37)
- Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis (2018) (37)
- Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis (2019) (36)
- Drug Insight: emerging therapies for amyloidosis (2006) (36)
- AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. (2009) (35)
- Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (2020) (34)
- The transthyretin amyloidoses: advances in therapy (2015) (33)
- Renal amyloidosis in intravenous drug users. (2006) (32)
- Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis (2011) (32)
- Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis (2018) (31)
- Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy (2019) (31)
- Inflammatory Bowel Disease and Systemic AA Amyloidosis (2013) (30)
- Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy (2015) (30)
- Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man (1999) (30)
- RNA-targeting and gene editing therapies for transthyretin amyloidosis (2022) (30)
- Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel (2017) (30)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. (2021) (28)
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial (2022) (28)
- A prospective study of nutritional status in immunoglobulin light chain amyloidosis (2013) (28)
- Analysis of the TTR gene in the investigation of amyloidosis: A 25‐year single UK center experience (2018) (25)
- Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis (2016) (24)
- Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. (2018) (23)
- Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis (2020) (22)
- Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance (2019) (22)
- Two types of amyloid in a single heart. (2014) (22)
- A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement (2018) (22)
- Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis. (2021) (21)
- A 24‐year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom (2019) (21)
- Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. (2022) (21)
- Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis (2018) (21)
- Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein (2016) (21)
- Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. (2010) (21)
- Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. (2017) (21)
- Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient (2014) (21)
- Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis - Results From the UK Amyloidosis Treatment Trial (2009) (19)
- nAddendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. (2021) (19)
- Amyloid Typing: Experience from a Large Referral Centre (2012) (19)
- Afro-Caribbean Heart Failure in the United KingdomCLINICAL PERSPECTIVE (2016) (18)
- A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo (2017) (18)
- Amyloid and the GI tract (2009) (18)
- 99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis (2021) (18)
- Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (2021) (18)
- Clinical and pathological phenotype of leukocyte cell-derived chemotaxin-2 (LECT2) amyloidosis (ALECT2) (2010) (17)
- Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study (2015) (17)
- Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre (2020) (17)
- Immunoparesis defined by heavy+light chain suppression is a novel marker of long‐term outcomes in cardiac AL amyloidosis (2017) (17)
- Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage (2020) (17)
- Tissue biopsy for the diagnosis of amyloidosis: experience from some centres (2021) (16)
- Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy (2000) (16)
- Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation (2009) (15)
- Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting (2014) (15)
- Cardiac Magnetic Resonance–Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid (2021) (15)
- Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (2021) (14)
- Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis (2015) (14)
- Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology (2017) (14)
- Renal transplantation in light chain amyloidosis: coming out of the cupboard. (2011) (14)
- ALchemy - A Large Prospective ‘Real World' Study of Chemotherapy in AL Amyloidosis (2011) (13)
- Renal transplant outcomes in amyloidosis. (2021) (13)
- A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis (2019) (13)
- Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment. (2009) (13)
- A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis (2010) (13)
- V122I transthyretin variant in elderly black Americans. (2015) (13)
- Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies (2017) (13)
- Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1 (2018) (13)
- European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease (2011) (12)
- A case report of hereditary apolipoprotein A-I amyloidosis associated with a novel APOA1 mutation and variable phenotype. (2016) (12)
- Proteomic Analysis for the Diagnosis of Fibrinogen Aα-chain Amyloidosis (2019) (12)
- Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report. (2006) (12)
- Systemic embolism in amyloid transthyretin cardiomyopathy (2022) (12)
- HIGH CUT-OFF HAEMODIALYSIS (HCO-HD) DOES NOT IMPROVE OUTCOMES IN MYELOMA CAST NEPHROPATHY: RESULTS OF EUROPEAN TRIAL OF FREE LIGHT CHAIN REMOVAL BY EXTENDED HAEMODIALYSIS IN CAST NEPHROPATHY (EULITE) (2016) (12)
- Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis (2014) (12)
- Cardiac Amyloidosis: A Review of Current Imaging Techniques (2021) (12)
- Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis (2008) (12)
- Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers (2019) (12)
- Decreasing incidence of AA amyloidosis in Spain (2013) (11)
- Systemic AL (light-chain) amyloidosis and the gastrointestinal tract (2009) (11)
- Spinal Stenosis in Familial Transthyretin Amyloidosis. (2019) (11)
- Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib (2021) (11)
- Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis (2020) (11)
- In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment. (2009) (10)
- Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience (2009) (10)
- A Matched Case Control Study of Doxycycline Added to Chemotherapy for Reducing Early Mortality in Patients with Advanced Cardiac AL Amyloidosis from the Alchemy Study Cohort (2014) (10)
- Efficacy of risk adapted cyclophosphamide, thalidomide and dexamethasone in systemic AL amyloidosis. (2005) (10)
- Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria (2019) (10)
- A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid (2017) (10)
- Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis (2015) (10)
- Measurement of liver and spleen interstitial volume in patients with systemic amyloid light-chain amyloidosis using equilibrium contrast CT (2017) (9)
- Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group (2018) (9)
- Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis (2008) (9)
- Extracellular volume with bolus‐only technique in amyloidosis patients: Diagnostic accuracy, correlation with other clinical cardiac measures, and ability to track changes in amyloid load over time (2018) (9)
- Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment (2022) (8)
- Renal amyloidosis. (2010) (8)
- Comparison of Free Light Chain Assays: Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. (2016) (8)
- Amyloid cardiomyopathy associated with a novel apolipoprotein A–I Q172P variant (2015) (8)
- The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis (2020) (8)
- Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry (2020) (8)
- DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience (2015) (8)
- The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis. (2020) (8)
- Value of antibodies to free light chains in immunoperoxidase studies of renal biopsies (2014) (8)
- Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue (2017) (8)
- Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation (2022) (8)
- Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis (2012) (7)
- Clinical profile and treatment outcome in 103 patients with al amyloidosis associated with IGM paraproteinaemia (2005) (7)
- 001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis (2017) (7)
- Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis (2022) (7)
- Curative hepatorenal transplantation for systemic amyloidosis associated with fibrinogen alpha-chain Glu526Val in an English family (1999) (7)
- Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis (2010) (7)
- Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis (2021) (7)
- Survival on dialysis and outcome after renal transplantation in AA amyloidosis (2010) (7)
- A PHASE 2, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EXPLORATORY CLINICAL ACTIVITY OF ALN-TTRSC, AN RNAI THERAPEUTIC FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (2015) (7)
- Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis (2006) (7)
- Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis (2022) (7)
- Imaging-Guided Treatment for Cardiac Amyloidosis (2022) (6)
- Misdiagnosing renal amyloidosis as minimal change disease. (2014) (6)
- A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP. (2009) (6)
- A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis (2021) (6)
- Retinal microangiopathy as an initial manifestation of familial amyloid cardiomyopathy associated with transthyretin e89k mutation. (2013) (6)
- Characterisation and management of vitreous and nerve amyloid in familial amyloid polyneuropathy due to variant transthyretin, Phe33Val (2007) (6)
- Karyomegalic interstitial nephritis with a novel FAN1 gene mutation and concurrent ALECT2 amyloidosis (2020) (6)
- Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein (2020) (6)
- Quality of life in ATTR amyloidosis (2015) (6)
- Transthyretin cardiac amyloidosis (2022) (6)
- Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study (2015) (6)
- Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils (2020) (6)
- Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years (2022) (5)
- Carpal Tunnel Biopsy Identifying Transthyretin Amyloidosis (2017) (5)
- Impact of afterload and infiltration on coexisting aortic stenosis and transthyretin amyloidosis (2021) (5)
- Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis. (2021) (5)
- Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis (2014) (5)
- Extracellular Volume Fraction by Computed Tomography Predicts Long-Term Prognosis Among Patients With Cardiac Amyloidosis. (2022) (5)
- CHARACTERISTICS AND OUTCOMES OF 714 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS -ANALYSIS OF A PROSPECTIVE OBSERVATIONAL STUDY (ALCHEMY STUDY) (2014) (5)
- AL amyloidosis Sequential heart and autologous stem cell transplantation for systemic (2013) (5)
- A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results (2019) (5)
- Correction to: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imaging (2021) (5)
- Use Of Plasma Cell Immunophenotype As Prognostic Markers In Patients With Systemic AL Amyloidosis (2013) (5)
- Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis". (2016) (5)
- Two types of systemic amyloidosis in a single patient (2020) (5)
- Outcome in systemic AL amyloidosis following stem cell transplantation or infusional chemotherapy. (2002) (5)
- Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms (2022) (5)
- Cumulative SAA production and outcome of AA amyloidosis (1999) (5)
- ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable (2021) (5)
- Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK (2022) (5)
- CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study (2010) (5)
- 028 Routine identification of hypoperfusion in cardiac amyloidosis by myocardial blood flow mapping (2017) (4)
- Amyloidosis Diagnosed in Solid Organ Transplant Recipients (2020) (4)
- Tissue doppler features of cardiac amyloidosis (2000) (4)
- UK AL Amyloidosis Treatment Trial (UKATT) - a randomised study: lessons for future trial design (2010) (4)
- Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis (2013) (4)
- Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy (2018) (4)
- Six-minute walk test (6MWT) in AL amyloidosis – baseline and 12-month follow-up after chemotherapy (2017) (4)
- Dose-Dependent Progressive Immunotherapeutic Clearance of Systemic Amyloid Deposits By Repeated Doses of Antibody to Serum Amyloid P Component (SAP) (2015) (4)
- Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment (2010) (4)
- Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy (2021) (4)
- Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis (2022) (4)
- Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis (2018) (4)
- Amyloid damage to islet β-cells in type 2 diabetes: hypoxia or pseudo-hypoxia? (2019) (4)
- A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred (2015) (4)
- Graded Renal Response Criteria for Light Chain (AL) Amyloidosis (2021) (4)
- HELIOS-A: RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (2022) (4)
- HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (2021) (3)
- Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres (2021) (3)
- Identification of wild‐type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS) (2022) (3)
- Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in 137 patients with systemic AL amyloidosis. (2002) (3)
- The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis (2020) (3)
- Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay. (2005) (3)
- N-terminal fragment of brain natriuretic peptide (NT-ProBNP) - a new response criterion in AL amyloidosis (2010) (3)
- Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real‐world longitudinal data (2021) (3)
- Challenges of Using NT-Probnp for Response Assessment in Systemic AL Amyloidosis - Analysis of a Prospective Study (2016) (3)
- High dose chemotherapy for systemic AL amyloidosis. (1999) (3)
- The role of renal transplantation in systemic AL amyloidosis. (2005) (3)
- Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients (2008) (3)
- The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis (2021) (3)
- Interim analysis of ALCHemy – a prospective study of 1000 patients with Systemic AL amyloidosis (2015) (3)
- Bleeding symptoms and coagulation test abnormalities in 308 patients with AL amyloidosis (1999) (3)
- M1263 Hepatic Al Amyloidosis - A 10-Year Experience at the United Kingdom National Amyloidosis Centre (NAC) (2010) (3)
- Transthyretin Ile84Thr is associated with familial amyloid polyneuropathy (2000) (3)
- Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK (2021) (3)
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply. (2021) (3)
- A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis. (2012) (3)
- High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. (2017) (3)
- Role of dual modality I123 serum amyloid P component SPECT-CT imaging in amyloidosis (2010) (3)
- N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T hold diagnostic value in cardiac amyloidosis (2023) (3)
- Comparison of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant (2008) (3)
- Combination chemotherapy for systemic AL amyloidosis (2001) (2)
- 137 PRIMARY RESULTS FROM APOLLO-B, A PHASE 3 STUDY OF PATISIRAN IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY (2022) (2)
- Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light‐chain (AL) amyloidosis (2021) (2)
- A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year (2017) (2)
- Regression of chronic kidney disease in a patient with AL amyloidosis: A case report . (2019) (2)
- Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non‐AL forms of the disease (2010) (2)
- The UK National Amyloidosis Centre. (2019) (2)
- Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant (2019) (2)
- Diagnostic dilemma and sudden death outcome: a case of amyloid cardiomyopathy. (2012) (2)
- Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis (2019) (2)
- The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma (2014) (2)
- Reply: Amyloidosis in the Era of Mass Spectrometry-Based Proteomics. (2018) (2)
- PATTERNS OF LATE GADOLINIUM ENHANCEMENT PREDICT SURVIVAL IN CARDIAC AMYLOIDOSIS: A SYSTEMATIC REVIEW OF 95 CASES WITH AL OR TTR TYPE (2012) (2)
- A UK consensus algorithm for early treatment modification in newly diagnosed systemic light‐chain amyloidosis (2022) (2)
- Abstract 14407: Regression of Cardiac AL Amyloid by Cardiovascular Magnetic Resonance (2016) (2)
- A review of the criteria for non-invasive diagnosis of cardiac transthyretin amyloidosis (2021) (2)
- Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years (2013) (2)
- A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis (2018) (2)
- Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis (2013) (2)
- Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study (2017) (2)
- Characteristics and natural history of early-stage cardiac transthyretin amyloidosis (2022) (2)
- Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis (2021) (2)
- Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis (2012) (2)
- Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis? (2016) (2)
- Light chain deposition disease (LCDD): a case series of 24 patients (2010) (2)
- Multi-Imaging Characterization of Cardiac Phenotype in Different Types of Amyloidosis. (2022) (2)
- Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave (2009) (2)
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging. (2021) (2)
- Natural history and outcome of amyloidosis in the elderly (2006) (1)
- Ixazomib, lenalidomide and dexamethasone in relapsed AL amyloidosis – a first report (2019) (1)
- Abstract 19388: Cardiovascular Magnetic Resonance in Cardiac Amyloidosis: A 242 Patient Prospective Study (2014) (1)
- SAA(1) alleles as risk factors in AA amyloidosis (1999) (1)
- NT-proBNP and High-Sensitivity Troponin T Hold Diagnostic Value in Cardiac Amyloidosis. (2022) (1)
- Occult senile cardiac amyloid in severe calcific aortic stenosis is not rare and has a poor prognosis: a 146 patient CMR biopsy study (2016) (1)
- Characterisation of cardiac amyloidosis associated with wild type transthyretin and the isoleucine 122 variant (2006) (1)
- Changes in the concentration of circulating free immunoglobulin light chains and outcome in systemic AL amyloidosis following chemotherapy. (2002) (1)
- 19 Myocardial perfusion mapping in cardiac amyloidosis- unearthing the spectrum from infiltration to ischaemia (2019) (1)
- Chapter 21 Amyloidosis (2008) (1)
- Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival, (2011) (1)
- Changes in serum NT-proBNP correlate with changes in both systolic and diastolic function in AL amyloidosis (2010) (1)
- Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis. (2012) (1)
- The Role of Liver Transplantation in Hereditary Non-Neuropathic Systemic Amyloidosis (2011) (1)
- ALchemy - a nationwide study of chemotherapy for systemic AL amyloidosis in the UK (2010) (1)
- Abstract 16030: Heterogeneity of Electrocardiographic Findings in Cardiac Transthyretin (ATTR) Amyloidosis and Impact on Survival (2014) (1)
- Solid Organ Transplantation in AL Amyloidosis: Lessons Learned and Its Current Role (2009) (1)
- Frequency of hereditary systemic amyloidosis masquerading as immunoglobulin light chain, AL (primary), amyloidosis. (2002) (1)
- Natural history of hereditary lysozyme amyloidosis (2010) (1)
- HIGH EARLY MORTALITY AND POOR OUTCOMES FOR PATIENTS WITH AL AMYLOIDOSIS PRESENTING WITH HIGH SERUM FREE LIGHT CHAINS - A NEW RISK STRATIFICATION MODEL (2009) (1)
- Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Commentary (2007) (1)
- The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre (2022) (1)
- When to suspect and how to approach a diagnosis of amyloidosis. (2022) (1)
- Detection of monoclonal free light chains by nephelometry in 262 patients with systemic AL amyloidosis. (2002) (1)
- Patisiran in patients with hATTR amyloidosis post-orthopedic liver transplant: 12-month results (2021) (1)
- Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (2020) (1)
- Five novel TTR variants: associated phenotypes and structural consequences (2015) (1)
- HEAVY/LIGHT CHAIN IMMUNOPARESIS AS A NOVEL MARKER OF POOR OUTCOMES IN SYSTEMIC AL AMYLOIDOSIS (2015) (1)
- Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis (2022) (1)
- Longterm Outcomes and Improved Renal Function with Autologous Stem Cell Transplantation (ASCT) in Light Chain Deposition Disease (LCDD) (2014) (1)
- Focal Segmental Glomerulosclerosis Complicating Therapy With Inotersen, an Antisense Oligonucleotide Inhibitor: A Case Report. (2022) (1)
- Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis (2021) (1)
- The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis (2020) (1)
- Letter by Treibel et al Regarding Article, "Sex-Related Discordance Between Aortic Valve Calcification and Hemodynamic Severity of Aortic Stenosis: Is Valvular Fibrosis the Explanation?" (2017) (1)
- The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis (2020) (1)
- Clinical ApoA‐IV amyloid is associated with fibrillogenic signal sequence (2021) (1)
- Diagnosing amyloid with a rectal biopsy-how important is it? (2009) (1)
- Localised amyloid at injection sites derived from porcine and human insulin (2010) (1)
- Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis. (2023) (1)
- Abstract 15710: Myocardial Ischaemia in Cardiac Amyloidosis, Changing Perspectives (2020) (1)
- Bleeding diathesis and prothrombotic tendencies in patients with newly diagnosed systemic light chain Amyloidosis: important clinical implications (2015) (1)
- Abnormal NT-ProBNP in AL Amyloidosis Patients without Cardiac Involvement at Diagnosis - A Predictor of Subsequent Cardiac Involvement. (2007) (1)
- Moderated Poster Session 4: Monday 4 May 2015, 15:30-16:30Room: Moderated Poster Area. (2015) (1)
- An unusual cause of carpal tunnel syndrome (2011) (1)
- A Prospective Study of Treatment Outcomes in 179 Patients with Advanced Cardiac Stage STAGE IIIb Amyloidosis (2015) (1)
- Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis (2013) (1)
- of liver transplantation -chain amyloidosis: clinical phenotype and role α Hereditary fibrinogen A (2013) (0)
- 17 Fat water imaging for sub-epicardial gadolinium: enhancing the diagnosis of myocarditis (2019) (0)
- NT-ProBNP in AL amyloidosis: changes after chemotherapy and association with survival (2006) (0)
- FRI0599 AA AMYLOIDOSIS IN RECIPIENTS OF CADAVERIC DERIVED PITUITARY GROWTH HORMONE – POTENTIAL EFFECT OF AN AMYLOID ENHANCING FACTOR? (2019) (0)
- Hepatic Amyloidosis in a Chronically Entangled Grey Seal (Halichoerus grypus). (2022) (0)
- Treatment of acquired transthyretin amyloidosis in domino liver transplantation (2022) (0)
- Alpha-1 antiprotease alleles as risk factors in AA amyloidosis (1999) (0)
- Abstract 14123: Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy (2018) (0)
- Studies of serum amyloid P component and anti-nuclear autoimmunity. (2004) (0)
- AN ANALYSIS OF THE ENDOCRINE DISEASE ASSOCIATED WITH SYSTEMIC AL AMYLOIDOSIS (2010) (0)
- Comparison of Different Technetium-99m-Labeled Bone Tracers for Imaging Cardiac Amyloidosis. (2022) (0)
- to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2— Evidence Base and Standardized Imaging Methods (2019) (0)
- Cardiac transplantation in transthyretin amyloid cardiomyopathy: Outcomes from three decades of tertiary center experience (2022) (0)
- Prognostic implications of clinical phenotype and severity of cardiac involvement in patients presenting with immunoglobulin light chain amyloidosis (2022) (0)
- LONG-TERM, INTEGRATED CARDIAC SAFETY OF PATISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY (2020) (0)
- Familial amyloid polyneuropathy: the importance of cardiac involvement (2015) (0)
- Mechano-enzymatic cleavage and TTR amyloidogenesis (2017) (0)
- Systemic Diseases (2010) (0)
- The Authors Reply. (2021) (0)
- Cardiac Followed by Autologous Stem Cell Transplantation for Systemic AL Amyloidosis. (2005) (0)
- Long‐term outcomes in light chain deposition disease‐analysis of a UK cohort (2022) (0)
- Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis (2023) (0)
- 103 Senile systemic amyloidosis: a common cause of heart failure in the elderly? (2011) (0)
- A white man with a very African form of hereditary amyloid cardiomyopathy. (2014) (0)
- A New Method of Response Assessment in AL Amyloidosis Using NT-ProBNP with Hematologic Response (2009) (0)
- Title Structure , Folding Dynamics , and Amyloidogenesis of D 76 N β 2-Microglobulin : ROLES OF SHEAR FLOW , HYDROPHOBIC SURFACES (0)
- Screening for patients with hereditary systemic amyloidosis (2006) (0)
- Length of Hospital Stay is an Independent Predictor of Overall Survival in Patients with systemic AL Amyloidosis (2017) (0)
- A profile of 44 long term survivors (> 10yrs) with AL amyloidosis (2007) (0)
- Experience of ATTR in a single centre: findings among 220 patients (2010) (0)
- Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel (2017) (0)
- Characterisation and treatment of hereditary and acquired systemic amyloidosis (2001) (0)
- 024 Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis (2017) (0)
- Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis (2009) (0)
- Title : Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology Running head : Anakinra in AA amyloidosis of uncertain aetiology (2017) (0)
- Laryngo-tracheobronchial amyloidosis - a 30 year institutional experience (2013) (0)
- AB0901 TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT (2019) (0)
- 954Assessment of Organ Dysfunction in Systemic AL Amyloidosis using Equilibrium MRI to calculate Extracellular Volume Fraction (2013) (0)
- Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen (2022) (0)
- Studies of serum amyloid P component (SAP) and antinuclear autoimmunity (2004) (0)
- Title: Changing Epidemiology of AA Amyloidosis – Clinical Observations Over 25 Years at a Single National Referral Centre Running head: Changing Epidemiology of AA Amyloidosis Key words: AA amyloidosis, Rheumatoid arthritis, Juvenile idiopathic arthritis, Systemic autoinflammatory disorders, Biologi (2018) (0)
- treatment outcome AL amyloidosis associated with IgM paraproteinaemia - clinical profile and (2013) (0)
- N-terminal pro natriuretic peptide type B ( NT-proBNP) is a reliable marker of cardiac response in patients with AL amyloidosis and renal failure (2010) (0)
- Risk Factors for Mortality in Patients with Hereditary Transthyretin-Mediated Amyloidosis: An Analysis of APOLLO and Global Open Label Extension Studies (2019) (0)
- Evaluation of methodologies for indirect comparison of eplontersen and vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy (P12-4.005) (2023) (0)
- The National Amyloidosis Centre, Royal Free Hospital and UCL, London (2019) (0)
- 008 Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study (2017) (0)
- 3 Treatment response in cardiac al amyloidosis assessed by CMR: findings at 3 months, 6 months and 1 year post-chemotherapy (2018) (0)
- 77 HELIOS-A: 18-MONTH EXPLORATORY CARDIAC RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (2022) (0)
- Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR) (2020) (0)
- Spotting senile systemic amyloidosis: why we miss it (2015) (0)
- LIGHT CHAIN DEPOSITION DISEASE (LCDD) VERSUS AL AMYLOIDOSIS: DIFFERENCES IN NATURAL HISTORY AND TREATMENT? (2010) (0)
- Incidence and predictors of worsening heart failure in patients with wild‐type transthyretin cardiac amyloidosis (2022) (0)
- Methods Patient Identification in the General Heart Failure (2016) (0)
- 172 CLINICAL AND PROGNOSTIC IMPLICATIONS OF RV UPTAKE WITH RADIONUCLIDE SCINTIGRAPHY IN TRANSTHYRETIN CARDIAC AMYLOIDOSIS (2022) (0)
- Assessment of left ventricular wall thickness in cardiac amyloidosis by different imaging modalities (2010) (0)
- Treatment outcomes of 299 elderly (>= 75 years) patients with systemic AL amyloidosis (2013) (0)
- Reductions in extracellular volume by magnetic resonance indicate ATTR cardiac amyloid regression with patisiran (2021) (0)
- prolonged progression-free survival amyloidosis is associated with high clonal response rates and Cyclophosphamide, bortezomib, and dexamethasone therapy in AL (2012) (0)
- The Authors Reply. (2020) (0)
- A PROFILE OF 140 LONG-TERM SURVIVORS WITH SYSTEMIC AL AMYLOIDOSIS (2014) (0)
- Transthyretin mutations in amyloidosis (1999) (0)
- CARDIAC UPTAKE IN AL AMYLOIDOSIS OF 99MTC-DPD AS A NOVEL MARKER OF POOR PROGNOSIS IN SYSTEMIC AL AMYLOIDOSIS (2016) (0)
- Correlation of bone marrow findings with organ distribution and amyloid burden in 103 patients with AL amyloidosis. (2000) (0)
- Atrial strain in cardiacATTR amyloidosis from pathophysiology to prognosis: is it time to rethink our approach to disease? (2020) (0)
- Progression, regression and redefining the treatment response – cardiac magnetic resonance with T1 and extracellular volume mapping in cardiac light-chain amyloidosis (2022) (0)
- Clinical Profiles and Outcomes in 1203 Newly Diagnosed Patients With Systemic AL Amyloidosis – First Analysis of the ALChemy Study. (2017) (0)
- Liver‐directed drugs for transthyretin‐mediated amyloidosis (2022) (0)
- AL amyloidosis in the elderly: A review of 330 patients (2008) (0)
- Reply (2018) (0)
- P119Oedema in amyloidosis: more than meets the eye (2019) (0)
- Hereditary systemic amyloidosis associated with three novel apolipoprotein AI variants (2010) (0)
- Cardiac transthyretin (ATTR) amyloidosis - clinical and echocardiographic findings from the largest single cohort worldwide (2013) (0)
- Size matters - redefining sex differences among patients with transthyretin amyloid cardiomyopathy – have we been wrong all along? (2022) (0)
- CLINICAL AND BIOCHEMICAL OUTCOME OF HEPATORENAL TRANSPLANTATION FOR HEREDITARY SYSTEMIC AMYLOIDOSIS ASSOCIATED WITH APOLIPOPROTEIN AI Gly26Arg1 (2001) (0)
- Comparison of 99mTc-DPD Scintigraphy, CMR Imaging, and Echocardiography in Patients With V30M-Associated Hereditary Transthyretin Amyloidosis. (2022) (0)
- Letter by Porcari et al Regarding Article, "Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation". (2022) (0)
- A Prospective Study Assessing Nutritional Status in Treatment-NaïVE AL Amyloidosis Patients and the Effects of Malnutrition on Quality of Life and Survival (2011) (0)
- P176Fat water gadolinium enhancement imaging in myocarditis: shifting the goalpost (2019) (0)
- 257 Carpal Tunnel Biopsy as a Diagnostic Tool to Identify Early Cases of Cardiac Amyloidosis: Results of a Pilot Study (2016) (0)
- SUN-187 LYSOZYME AMYLOIDOSIS – TWO NOVEL CASES WITH NEWLY DESCRIBED GENETIC MUTATIONS (2019) (0)
- Amyloid and immunotactoid glomerulopathy (2008) (0)
- The UK Experience of Renal Transplantation in AL Amyloidosis (2019) (0)
- Phenotype and natural history of transthyretin alanine 60 ( T60A) amyloidosis (2010) (0)
- Remarkable Efficacy of IL 1 Receptor Antagonist In Schnitzler's Syndrome a Series of 6 Cases (2010) (0)
- Renal amyloidosis in injection drug users. Q J Med 2006; (In press) (2006) (0)
- Fibrinogen Aα-chain Amyloidosis: Clinical features and the role of combined liver and kidney transplantation. (2005) (0)
- Abstract 16829: Myocardial Extracellular Volume Fraction and Survival in Systemic AL Amyloidosis (2013) (0)
- Acute changes in cardiac structural and tissue characterisation parameters following haemodialysis measured using cardiovascular magnetic resonance (2019) (0)
- PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS (2019) (0)
- S1099 Systemic AA Amyloidosis in Crohn's Disease (CD): A Serum Amyloid P Component (SAP) Scintigraphy Study (2009) (0)
- Fibrinogen A alpha-chain amyloidosis: Clinical features and the role of combined liver and kidney transplantation (2005) (0)
- Changes in referral pathway and phenotypic status of patients diagnosed with ATTR cardiac amyloidosis during the past 20 years (2022) (0)
- Title: Immunoparesis defined by heavy+light chain suppression is a novel marker of long- term outcomes in cardiac AL amyloidosis Running title: HLC suppression in AL amyloidosis Authors and affiliations: (2018) (0)
- A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis (2019) (0)
- 189 PREVALENCE, DISEASE CHARACTERISTICS AND OUTCOMES OF HEREDITARY TRANSTHYRETIN AMYLOID CARDIOMYOPATHY AMONG ELDERLY INDIVIDUALS (2022) (0)
- Native T 1 and ECV in ATTR amyloidosis (2018) (0)
- Clinical outcome of systemic AL amyloidosis affecting the kidneys (2010) (0)
- The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy (2020) (0)
- Global longitudinal strain predicts survival and response in patients with systemic AL amyloidosis. analysis of 915 patients from the ALchemy prospective trial (2020) (0)
- A pilot study of the tolerability, safety and efficacy of CPHPC in patients with systemic amyloidosis (2006) (0)
- Exploratory Analyses From Apollo-B, A Phase 3 Study Of Patisiran In Patients With Attr Amyloidosis With Cardiomyopathy (2023) (0)
- Heavy/light chain immunoparesis identifies systemic AL amyloidosis patients with poor survival outcomes (2015) (0)
- Early-Onset Leptomeningeal Manifestation of G47R Hereditary Transthyretin Amyloidosis (2021) (0)
- Myocardial ischaemia in cardiac amyloidosis: a change of perspective (2022) (0)
- Correction to: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization (2021) (0)
- Unraveling the clonal B cell disease underlying localised AL amyloidosis (2010) (0)
- RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis (2023) (0)
- NT-ProBNP in AL amyloidosis: association with survival and changes after chemotherapy (2007) (0)
- Prognostic implications of biventricular uptake of bone tracers at planar scintigraphy in transthyretin cardiac amyloidosis (2022) (0)
- High prevalence of sleep disordered breathing (SDB) in patients with systemic AL amyloidosis (2014) (0)
- Cardiac Magnetic Resonance derived Extracellular Volume Mapping for the quantification of hepatic and splenic amyloid Short title: Quantifying extra-cardiac amyloid with ECV mapping (2021) (0)
- Hereditary systemic amyloidosis due to variant fibrinogen A alpha-chain is unexpectedly frequent in the British population (2001) (0)
- A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis (2014) (0)
- [Incidental finding of leukocyte cell-derived chemotaxin 2 - Associated amyloidosis in a liver]. (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Julian David Gillmore?
Julian David Gillmore is affiliated with the following schools:
